Education event for occupational and environmental medicine physicians will cover biomechanics, research and clinical indications for use of long-duration ultrasound treatment for soft-tissue injury healing.
Read MoreThe closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, nutraceuticals, and supplements
Aspire has multiple product candidates in key areas of medical needs such as a fast-acting aspirin product for cardiology emergencies and pain management, a proprietary Viagra/Cialis combination product, various bi-hormonal drugs such as testosterone, estrogen, weight loss, anti-seizure, and thyroid drugs. Supplements such as pre-workout and melatonin are already being developed using Aspire's proprietary sublingual delivery system.
Aspire Biopharma Holdings, Inc. ("Aspire Biopharma") is scheduled to begin trading on Nasdaq on February 20, 2025 under the ticker symbol "ASBP".
Read MoreFourth Quarter Highlights
Per Class B share(3): $1.02 adjusted basic earnings up 5.2%; $1.01 basic earnings up 359.1%; $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.01 per share
Sales increased 9.0% on 6.8% organic growth, 1.4% acquisition growth and 0.8% positive currency translation
CCL, Checkpoint and Innovia posted organic sales growth of 5.4%, 13.3%, and 20.2%, respectively, partly offset by an organic decline for Avery of 2.0%
Operating income(1) improved 5.1%, with a 14.8% operating margin(1) down 50 bps
2024 Highlights
Per Class B share(3): $4.32 adjusted basic earnings up 14.9%; $4.73 basic earnings up 58.2%; $0.44 revaluation gain included in 2024 basic earnings and $0.54 goodwill impairment loss in 2023 basic earnings; currency translation negative $0.02 per share
Sales increased 9.0% on 6.1% organic growth, 2.3% acquisition growth and 0.6% positive currency translation
Operating income(1) improved 13.0%, with a 15.8% operating margin(1) up 60 bps
SHPE and Latino Donor Collaborative released a report with key facts showcasing a 60% increase for Hispanics in AI technical roles and rising STEM degrees for Latinos that help drive the U.S. economy forward.
Read More
Founder and Chief Executive Officer is Alan Sheriff, a former Vice Chairman of PNC Bank, a founder and former Co-CEO of Solebury Capital, and former Co-Head of Equity Capital Markets, Americas, Credit Suisse First Boston
Read MoreThis study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions
Availability of first IIT proof-of-concept results potentially in H1 2025
Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID
Read More
The global leader in dental imaging technologies will showcase the latest innovations added to its digital ecosystem - a suite of tools and software designed to connect the entire digital workflow from diagnosis to delivery.
Read More
New Mobile App to Offer Enhanced Features for Fans to Connect with Athletes, Celebrities, and Influencers, Opening Up New Revenue Streams for Fantribe and Tritent International
Read More
